# Applicant

Focus Diagnostics, Inc. 10703 Progress Way Cypress, California 90630 USA

# Establishment Registration No. 2023365

# AUG - 4 2008

Contact Person

Constance Bridges tel 714.220.1900 fax 714.995.6921 cbridges@focusdx.com

# Summary Date

June 27, 2008

Proprietary Name Generic Name Classification Predicate Devices

Plexus EBV IgM Multi-Analyte Diagnostics   
Epstein-Barr Virus Serological Assays   
Class I   
Osom@ Mono Test   
Diamedix EBV VCA IgM ELISA   
Athena Multi-Lyte EBV VCA IgM Test System   
Epstein-Barr Virus VCA (IgM) Recomb Immun Antibod

# Device Description

Multiplexed Imunoassay or he Qualitative Detection  Human IgM Antibodies toEpstein-Bar Viu

# Intended Use

Foc Diagostic' PlexuEBV IgM Mui-Analyte Diagostics st ki is intended or qualiativelydetc the presence or absence of human IgM class antibodies to viral capsid antigen (VCA), and heterophile antibodies in huan sera.The test is indicated as an aid in the diagnosis of EBV infection and EBV-associated infecious mononucleosis.

The perormancf this assay has ot bcn cstablished or use in the diagnosisof asopharyngeal carcinoa nd Burki ho r stin pi patntrue y  pont a cil r  wh automated equipment. This assay has not been evaluated for donor screening.

The Focus Diagnostics Plexus EBV IgM uses an Antigen Bead suspension that contains two distinct EBV antg b tyes (VCA nd Hetephind e roc conol bead type that fuor  differnt waveengh nd/o intensities.

The Focus Diagnostics PlexusTM EBV IgM is a three step procedure.

1. Pt erilu n heilu rc wi Ant Bea.I noi then the antibodies bind to the corresponding antigen beads.   
2. Phycoerythrin-conjugated goat Anti-human IgM (Conjugate) is added, binds to the bound EBV antibody (if present), and forms a Conjugate-EBV antibody-antigen bead sandwich.   
3. Fl  nt   ai  l

Comparison with Predicate Devices: VCA IgM analyte:   

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=3>Predicates</td></tr><tr><td rowspan=1 colspan=1>Name</td><td rowspan=1 colspan=1>PlexusTM EBV IgMMulti-AnalyteDiagnostics</td><td rowspan=1 colspan=1>Diamedix VCA IgM,ELISA</td><td rowspan=1 colspan=1>Athena Multi-LyteEBV VCA IgM TestSystem</td><td rowspan=1 colspan=1>Epstein-Barr VirusVCA (IgM) RecombImmun Antibod(IFA)</td></tr><tr><td rowspan=1 colspan=1>Similarities between Device and Predicate</td><td rowspan=1 colspan=1>Similarities between Device and Predicate</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>Focus Diagnostics&#x27;PlexusTM EBV (VCA)IgM Multi-AnalyteDiagnostics test kit isintended forqualitatively detectingthe presence or absenceof human IgM classantibodies to viral capsidantigen (VCA), andheterophile antibodies inhuman sera. The test isindicated as an aid in thediagnosis of EBVinfection and EBV.associated infectiousmononucleosis.</td><td rowspan=1 colspan=1>Diamedix Corp EBVVCA IgM ELISA isintended for thequalitative and semi-quantitative determinationof IgM antibodies toEpstein-Barr Virus(recombinant) viral capsidantigen (EBV-VCA IgM)in human serum byindirect enzymeimmunoassay. The Is-EBV-VCA IgM test kitmay be used incombination with otherEpstein-Barr serologies,Viral Capsid Antigen(VCA) IgG, Epstein-BarrNuclear Antigen-1(EBNA-I) IgG and IgM,Early Antigen-Diffuse(EA-D) IgG and IgM andheterophile antibody, asan aid in the diagnosis ofinfectious mononucleosis(IM).</td><td rowspan=1 colspan=1>The Zeus Scientific,Inc. AtheNA Multi-Lyte® EBV VCAIgM Test System is amicroparticlc-basedimmunoassayintended for thequalitative detectionof IgM class antibodyto Epstein-Barr virus,viral capsid antigen inhuman serum. Thetest system isintended to be usedfor the laboratorydiagnosis of EBV-associated infectiousmononucleosis andprovidesepidemiologicalinformation on thediseases caused byEpstein-Barr virus.</td><td rowspan=1 colspan=1>Focus Diagnostics&#x27;Epstcin-Barr VirusViral Capsid Antigens(EBV VCA) IgGImmunofluorescenceAntibody (IFA) test isintended for thedetection and scmi-quantitation of humanIgG antibodics to theviral capsid antigens(VCA) of Epstein-Barrvirus in human serumas an aid in the clinicaldiagnosis of infectiousmononuclcosis.</td></tr><tr><td rowspan=1 colspan=1>Indications for use</td><td rowspan=1 colspan=1>The test is indicated asan aid in the diagnosis ofEBV infection andEBV-associatedinfectiousmononucleosis.</td><td rowspan=1 colspan=1>The device is indicated foruse with patients with thesigns and symptoms ofinfectious mononuclcosis.</td><td rowspan=1 colspan=1>The device isindicated forlaboratory diagnosisof EBV-associatedinfectiousmononucleosis and toprovideepidemiologicalinformation on thediseases caused byEpstein-Barr virus</td><td rowspan=1 colspan=1>The test is indicated asan aid in the clinicaldiagnosis of infectiousmononucleosis.</td></tr><tr><td rowspan=1 colspan=1>ImmunoglobulinType</td><td rowspan=1 colspan=1>IgM</td><td rowspan=1 colspan=1>lgM</td><td rowspan=1 colspan=1>IgM</td><td rowspan=1 colspan=1>IgM</td></tr><tr><td rowspan=1 colspan=1>Sample matrix</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>CLIA complexity</td><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>High</td></tr><tr><td rowspan=1 colspan=1>Difference between</td><td rowspan=1 colspan=4>Difference between Device and Predicate</td></tr><tr><td rowspan=1 colspan=1>Antigen</td><td rowspan=1 colspan=1>EBV-VCA: VCA gP125, affinity purified</td><td rowspan=1 colspan=1>EBV-VCA: Recombinant47 kDa fusion half of p18</td><td rowspan=1 colspan=1>EBV VCA pg125</td><td rowspan=1 colspan=1>Recombinant VCAantigen (rVCA)</td></tr></table>

# K073381

510(k) Summary of Safety and Effectiveness Plexus EBV IgM Multi-Analyte Diagnostics Catalog No. MP0600M Prepared Date: July 22, 2008 Page 3 of 13   

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=3>Predicates</td></tr><tr><td rowspan=1 colspan=1>Name</td><td rowspan=1 colspan=1>Plexus™M EBV IgMMulti-AnalyteDiagnostics</td><td rowspan=1 colspan=1>Diamedix VCA IgM,ELISA</td><td rowspan=1 colspan=1>Athena Multi-LyteEBV VCA IgM TestSystem</td><td rowspan=1 colspan=1>Epstein-Barr VirusVCA (IgM) RecombImmun Antibod(IFA)</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>antigen</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Strain</td><td rowspan=1 colspan=1>N/A- purified protein</td><td rowspan=1 colspan=1>N/A- Recombinant protein</td><td rowspan=1 colspan=1>N/A native protcin</td><td rowspan=1 colspan=1>N/A- Recombinantprotein</td></tr><tr><td rowspan=1 colspan=1>Host Cell Line</td><td rowspan=1 colspan=1>EBV-VCA: Native(P3H or P3HR-1)</td><td rowspan=1 colspan=1>EBV-VCA: E. coli(unknown)</td><td rowspan=1 colspan=1>Unknown</td><td rowspan=1 colspan=1>Mammalian cell line</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Multiplex MicrobeadImmunoassay (MMIA)based on Luminex XMAPtechnology</td><td rowspan=1 colspan=1>Enzyme Immunoassaytechnology.</td><td rowspan=1 colspan=1>Flow cytometryimmunoassay</td><td rowspan=1 colspan=1>IndirectImmunofluorescenceAntibody Test</td></tr><tr><td rowspan=1 colspan=1>Interpretation oftest results</td><td rowspan=1 colspan=1>Perform automatedcalculations usingPlexus software.</td><td rowspan=1 colspan=1>Manual calculation</td><td rowspan=1 colspan=1>AtheNA Multi-Lyteinstrumcnt</td><td rowspan=1 colspan=1>Manual</td></tr></table>

# Comparison with Predicate Devices: Heterophile $\boldsymbol { \mathrm { I g } } \boldsymbol { \mathrm { M } }$ analyte:

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Name</td><td rowspan=1 colspan=1>Plexus™M EBV IgM Multi-AnalyteDiagnostics</td><td rowspan=1 colspan=1>Osom® Mono Test, Heterophile</td></tr><tr><td rowspan=1 colspan=3>Similarity between Device and Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>Focus Diagnostics&#x27; PlexusTM EBV(Heterophile) IgM Multi-Analyte Diagnosticstest kit is intended for qualitatively detectingthe presence or absence of human IgM classantibodies to viral capsid antigen (VCA), andheterophile antibodies in human sera. Thc tcstis indicated as an aid in the diagnosis of EBVinfection and EBV-associated infectiousmononucleosis.</td><td rowspan=1 colspan=1>The OSOM Mono Test is intended for the quantitativedetection infectious mononucleosis hcterophileantibodics in serum, plasma and whole blood as an aidin the diagnosis of infectious mononucleosis.</td></tr><tr><td rowspan=1 colspan=1>Indications for use</td><td rowspan=1 colspan=1>The test is indicated as an aid in the diagnosisof EBV infection and EBV-associatedinfectious mononucleosis.</td><td rowspan=1 colspan=1>Intended to make a serological diagnosis of EBVinfections</td></tr><tr><td rowspan=1 colspan=1>ImmunoglobulinType</td><td rowspan=1 colspan=1>IgM</td><td rowspan=1 colspan=1>IgM</td></tr><tr><td rowspan=1 colspan=3>Difference between Device and Predicate</td></tr><tr><td rowspan=1 colspan=1>Sample matrix</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Serum / Plasma / Whole Blood</td></tr><tr><td rowspan=1 colspan=1>CLIA complexity</td><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>Moderate</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Multiplex Microbead Immunoassay (MMIA)based on Luminex XMAP technology.</td><td rowspan=1 colspan=1>Immunocheomatorgraphic Test</td></tr></table>

# K073381

510(k) Summary of Safety and Effectiveness Plexus EBV IgM Multi-Analyte Diagnostics Catalog No. MP0600M Prepared Date: July 22, 2008 Page 4 of 13

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Name</td><td rowspan=1 colspan=1>Plexus™ EBV IgM Multi-AnalyteDiagnostics</td><td rowspan=1 colspan=1>Osom® Mono Test, Heterophile</td></tr><tr><td rowspan=1 colspan=1>Strain</td><td rowspan=1 colspan=1>NA purified protein</td><td rowspan=1 colspan=1>NA native protein</td></tr><tr><td rowspan=1 colspan=1>Host Cell Line</td><td rowspan=1 colspan=1>Purificd from bovine red blood cells</td><td rowspan=1 colspan=1>Extract of bovine erythrocytes</td></tr><tr><td rowspan=1 colspan=1>Antigen</td><td rowspan=1 colspan=1>Heterophile: purified protein</td><td rowspan=1 colspan=1>Heterophilc: native protcin</td></tr><tr><td rowspan=1 colspan=1>Interpretation oftest results</td><td rowspan=1 colspan=1>Perform automated calculations using Plexussoftware.</td><td rowspan=1 colspan=1>Visual evaluation</td></tr></table>

# EXPECTED VALUES

$( n = 7 2 3 . )$ from a Total Population $( N = 7 2 3 )$ .For all analytes, index values of $\mathtt { < 0 . 9 0 }$ are negative, $\mathtt { z 0 . 9 0 }$ to $\leq 1 . 1 0$ are equivocal and $> 1 . 1 0$ are positives.

<table><tr><td rowspan=1 colspan=3>Table 1: Observed Prevalence - EBV Plexus</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>VCA IgM</td><td rowspan=1 colspan=1>Heterophile</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>12.7% (92/723)</td><td rowspan=1 colspan=1>9.3% (67/723)</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0.6% (4/723)</td><td rowspan=1 colspan=1>0% (0/723)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>86.7% (627/723)</td><td rowspan=1 colspan=1>90.7% (656/723)</td></tr></table>

Table 2: EBV Plexus Results VCA IgM   

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Positive</td><td rowspan=1 colspan=2>Equivocal</td><td rowspan=1 colspan=2>Negative</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Age</td><td rowspan=1 colspan=1>Gender</td><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>&lt;5</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>6.7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>93.3</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>&lt;5</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>94.4</td><td rowspan=1 colspan=1>36</td></tr><tr><td rowspan=1 colspan=1>5-12</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>5-12</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>89</td><td rowspan=1 colspan=1>93.7</td><td rowspan=1 colspan=1>95</td></tr><tr><td rowspan=1 colspan=1>13-20</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>16.8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>139</td><td rowspan=1 colspan=1>83.2</td><td rowspan=1 colspan=1>167</td></tr><tr><td rowspan=1 colspan=1>13-20</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>18.5</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>105</td><td rowspan=1 colspan=1>80.8</td><td rowspan=1 colspan=1>130</td></tr><tr><td rowspan=1 colspan=1>21-30</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>18.4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>81.6</td><td rowspan=1 colspan=1>38</td></tr><tr><td rowspan=1 colspan=1>21-30</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>27.8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>72.2</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=1 colspan=1>31-40</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>93.8</td><td rowspan=1 colspan=1>16</td></tr><tr><td rowspan=1 colspan=1>31-40</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>7.1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>92.9</td><td rowspan=1 colspan=1>14</td></tr><tr><td rowspan=1 colspan=1>41-50</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>15.8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>84.2</td><td rowspan=1 colspan=1>19</td></tr><tr><td rowspan=1 colspan=1>41-50</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>7.7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>92.3</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>51-60</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>87.5</td><td rowspan=1 colspan=1>16</td></tr><tr><td rowspan=1 colspan=1>51-60</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>61-70</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>9</td></tr></table>

# K073381

510(k) Summary of Safety and Effectiveness Plexus EBV IgM Multi-Analyte Diagnostics Catalog No. MP0600M Prepared Date: July 22, 2008 Page 5 of 13   

<table><tr><td rowspan=1 colspan=9>Table 2: EBV Plexus Results VCA IgM</td></tr><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Positive</td><td rowspan=1 colspan=2>Equivocal</td><td rowspan=1 colspan=2>Negative</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Age</td><td rowspan=1 colspan=1>Gender</td><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>61-70</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>&gt;70</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>7</td></tr><tr><td rowspan=1 colspan=1>&gt;70Total</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>192</td><td rowspan=1 colspan=1>11.112.7</td><td rowspan=1 colspan=1>04</td><td rowspan=1 colspan=1>00.6</td><td rowspan=1 colspan=1>8627</td><td rowspan=1 colspan=1>88.986.7</td><td rowspan=1 colspan=1>9723</td></tr></table>

<table><tr><td rowspan=1 colspan=9>Table 3: EBV Plexus Results Heterophile IgM</td></tr><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Positive</td><td rowspan=1 colspan=2>Equivocal</td><td rowspan=1 colspan=2>Negative</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Age</td><td rowspan=1 colspan=1>Gender</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>&lt;5</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>&lt;5</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>94.4</td><td rowspan=1 colspan=1>36</td></tr><tr><td rowspan=1 colspan=1>5-12</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>95</td><td rowspan=1 colspan=1>95</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>5-12</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>91</td><td rowspan=1 colspan=1>95.8</td><td rowspan=1 colspan=1>95</td></tr><tr><td rowspan=1 colspan=1>13-20</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>12.6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>146</td><td rowspan=1 colspan=1>87.4</td><td rowspan=1 colspan=1>167</td></tr><tr><td rowspan=1 colspan=1>13-20</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>18.5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>106</td><td rowspan=1 colspan=1>81.5</td><td rowspan=1 colspan=1>130</td></tr><tr><td rowspan=1 colspan=1>21-30</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>13.2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>86.8</td><td rowspan=1 colspan=1>38</td></tr><tr><td rowspan=1 colspan=1>21-30</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>s</td><td rowspan=1 colspan=1>27.8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>72.2</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=1 colspan=1>31-40</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>I5</td><td rowspan=1 colspan=1>93.8</td><td rowspan=1 colspan=1>16</td></tr><tr><td rowspan=1 colspan=1>31-40</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>14</td></tr><tr><td rowspan=1 colspan=1>41-50</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>19</td></tr><tr><td rowspan=1 colspan=1>41-50</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>o</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>51-60</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>16</td></tr><tr><td rowspan=1 colspan=1>51-60</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>61-70</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>9</td></tr><tr><td rowspan=1 colspan=1>61-70</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>&gt;70</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>7</td></tr><tr><td rowspan=1 colspan=1>&gt;70Total</td><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>067</td><td rowspan=1 colspan=1>09.3</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>9656</td><td rowspan=1 colspan=1>10090.7</td><td rowspan=1 colspan=1>9723</td></tr></table>

The table below summarizes the breakdown of the samples age and gender information. The distribution char below exhibits the age distribution of all 873 samples included in the study.

<table><tr><td colspan="3">Age Information:</td></tr><tr><td>Summary of Female Subjects</td><td>Summary of Male Subjects</td><td></td></tr><tr><td>n</td><td>474</td><td>399</td></tr><tr><td>mean</td><td>20.0</td><td>18.3</td></tr><tr><td>median</td><td>16.0</td><td>14.0</td></tr><tr><td>min</td><td>1</td><td>1</td></tr><tr><td>max</td><td>88</td><td>87</td></tr></table>

![](images/8c4061b062e2008d0b2744cb565bf51cee894d17c48ba0bb984a9146b1b3fc03.jpg)

# PERFORMANCE CHARACTERISTICS

# Typical Antibody Response Classification

The table below summarizes a generally accepted algorithn for classifying the EBV infection status via EBV serologic profiles.

<table><tr><td rowspan=1 colspan=2>EBV SerologicalStatus</td><td rowspan=1 colspan=1>EBNA-1 IgG</td><td rowspan=1 colspan=1>EBV VCA IgG</td><td rowspan=1 colspan=1>EBV EA-D IgG</td><td rowspan=1 colspan=1>EBV VCA IgM</td><td rowspan=1 colspan=1>HeterophileAntibody</td></tr><tr><td rowspan=14 colspan=1>Acute</td><td rowspan=8 colspan=1>PrimaryAcute</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=6 colspan=1>IateAcute</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=2>Recovering</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=2>Past Infection</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=2>No Infection</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=2>Indeterminant</td><td rowspan=1 colspan=5>Combinations not listed above (n =-18)</td></tr></table>

# Comparison Studies

Performance of the Plexus EBV VCA IgM analyte was tested against a combination (hereafter referred to as 'consensus predicate) of a FDA-cleared commercially available ELISA, a FDA clcarcd commercially available immunofluroscent (IFA) test and a FDA cleared commercially available flow cytomctry bascd immunoassay. For each sample, a consensus based algorithm $( 2 / 3 )$ was used to determine the predicate result for comparison with the Plexus VCA IgM result. The Plexus EBV Heterophile $\mathbf { \boldsymbol { \mathrm { I g M } } }$ analyte was tested against a FDA cleared heterophile T n a peiatric hospital laboratory locate in the Mid-West, and Focus with serum samples in which EBV ests were oThea wee sequentially suite the laboraory archivandmaskeSampls wee colle three sites and include both prospective $\mathbf { ( n = 7 2 3 ) }$ and retrospective $( \mathfrak { n } = 1 5 0 )$ specimens. The Plexus EBV IgM tests were run in conjunctin with the Plexus EBV IgG tests or a completc antibody profil.The samples were then classified into EBV infection status using the Serological Status table abovc.

Prospective Population Samples: Plexus EBV vs. Consensus Predicate for VCA IgM analyte $( N = 7 2 . 3 )$ Samples were collected and tested by the Northeast investigator $( n = 3 5 0 )$ ,Mid-West investigator $( n = 2 4 9 )$ and Focus $( n = 1 2 4 )$ .

The following table outlines the positive and negative percent agreements for prospective samples for VCA IgM analyte when the consensus predicate is used for VCA $\mathrm { { I g M } }$ analysis.

<table><tr><td rowspan=1 colspan=6>Table 4: EBV VCA IgM Results</td></tr><tr><td rowspan=1 colspan=1>Consensus Predicate</td><td rowspan=1 colspan=5>Plexus</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>85.9%(79/92), 95% CI:77.3-91.6%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>630</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>617</td><td rowspan=1 colspan=1>97.8%(617/631), 95% C1:96. 3-98.7%</td></tr></table>

# K073381

510(k) Summary of Safety and Effectiveness Plexus EBV IgM Multi-Analyte Diagnostics Catalog No. MP0600M Prepared Date: July 22, 2008 Page 8 of 13

<table><tr><td rowspan=1 colspan=6>Table 4: EBV VCA IgM Results</td></tr><tr><td rowspan=1 colspan=1>Consensus Predicate</td><td rowspan=1 colspan=5>Plexus</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>No consensus1</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>NA</td></tr></table>

obtained

Prospective Population Samples: Plexus EBV vs. Heterophile Rapid Test for Heterophile IgM analyte $( N = 7 2 3 )$ EY Samples were collected and tested by the Northeast investigator $( n ~ = ~ 3 5 0 )$ ,Mid-West investigator $( n = 2 4 9 )$ and Focus $( n = 1 2 4 )$ .

Th fllowing tabloutines the posiiveand ngtiv prnt agreements or prospecive samples o Hethile $\mathbf { I g } \mathbf { M }$ analyte whcn thc Heterophile rapid test is used as predicate for Heterophile IgM analysis and consensus predicate is used for VCA $\mathbf { I g } \mathbf { M }$ analysis.

<table><tr><td rowspan=1 colspan=6>Table 5: EBV Heterophile Results</td></tr><tr><td rowspan=2 colspan=1>Predicate Rapid Test</td><td rowspan=1 colspan=5>Plexus</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>80%(60/75), 95% CI:69.6-87.5%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>648</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>641</td><td rowspan=1 colspan=1>98.9%(641/648), 95% CI:97.8-99.5%</td></tr></table>

Prpective Populatio Samples: Pexus EBVvs. Consensus Predicate r VCA IgM analyte (by Serological Staus) $( N = 7 2 3 )$

Samples were collected and tested by the Northeast investigator $( n = 3 5 0 )$ , Mid-West investigator $( n = 2 4 9 )$ and Focus $( n - 1 2 4 )$ .

Th owigablute the posiivnd negativeperent areet aros varus soogiccassn for prospective samples for VCA IgM analyte when the consensus predicate is used for VCA IgM analysis.

<table><tr><td rowspan=1 colspan=8>Table 6: EBV VCA IgM Results</td></tr><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Consensus Predicate</td><td rowspan=1 colspan=3>Plexus</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=2>Serostatus byPredicates</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=6 colspan=1>Acute</td><td rowspan=3 colspan=1>PrimaryAcute</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>94.9%(56/59), 95% CI:86.1-98.3%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100%(1/1), 95% CI:20.7-100%</td></tr><tr><td rowspan=1 colspan=1>No consensus</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=3 colspan=1>LateAcute</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>64.3%(9/14), 95% CI:38.8-83.7%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>96.6%(56/58), 95% CI:88.3-99%</td></tr><tr><td rowspan=1 colspan=1>No consensus</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=2>Recovering</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=2>Recovering</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100%(1/1), 95% CI:20.7-100%</td></tr><tr><td rowspan=1 colspan=2>Recovering</td><td rowspan=1 colspan=1>No consensus</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=2>Previous Infection</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0%(0/1), 95% CI:0-79.3%</td></tr><tr><td rowspan=1 colspan=2>Previous Infection</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>296</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>286</td><td rowspan=1 colspan=1>96.3%(286/297), 95% CI:93.5-97.9%</td></tr><tr><td rowspan=1 colspan=2>Previous Infection</td><td rowspan=1 colspan=1>No consensus1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=2>No Infection</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>50%(1/2), 95% C:9.5-90.5%</td></tr></table>

# K073381

510(k) Summary of Safety and Effectiveness Plexus EBV IgM Multi-Analyte Diagnostics Catalog No. MP0600M Prepared Date: July 22, 2008 Page 9 of 13

<table><tr><td rowspan=1 colspan=7>Table 6: EBV VCA IgM Results</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Consensus Predicate</td><td rowspan=1 colspan=3>Plexus</td><td rowspan=1 colspan=1>Y</td></tr><tr><td rowspan=1 colspan=1>Serostatus byPredicates</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>No Infection</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>100%(225/225), 95% CI:98.3-100%</td></tr><tr><td rowspan=1 colspan=1>No Infection</td><td rowspan=1 colspan=1>No consensus&#x27;</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Indeterminate</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>81.3%(13/16), 95% CI:57.0-93.4%</td></tr><tr><td rowspan=1 colspan=1>Indeterminate</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>98%(48/49), 95% CI:89.3-99.6%</td></tr><tr><td rowspan=1 colspan=1>Indeterminate</td><td rowspan=1 colspan=1>No consensus</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>NA</td></tr></table>

obtained.

Prospectiv Population Samples: Plexus EBV vs. Heterophile Rapid Test or Heterophile IgM analye (by Serological Status) $( N = 7 2 3 )$

Samples were collected and tested by the Northeast investigator $( n ~ \approx ~ 3 5 0 )$ ,Mid-West investigator $( n { = } 2 4 9 )$ , and Focus $( n - 1 2 4 )$ .

Th lowigabuie posivnegaiv prnt greet cros varus rologiclcassi for prospective samples for Heterophile $\bf { I g M }$ analyte when the Heterophile rapid test is used as predicate for Heterophile $\mathbf { J g M }$ analysis and consensus predicate is used for VCA IgM analysis.

<table><tr><td rowspan=1 colspan=8>Table 7: EBV Heterophile IgM Results</td></tr><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Predicate HeterophileRapid Test</td><td rowspan=1 colspan=3>Plexus</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=2>Serological Status byPredicates</td><td rowspan=1 colspan=1>Primary Acute</td><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=6 colspan=1>Acute</td><td rowspan=3 colspan=1>PrimaryAcute</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>94.1%(48/51), 95% CI:84.1-98%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>88.9%(8/9), 95% CI:56.5-98%</td></tr><tr><td rowspan=3 colspan=1>LateAcute</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>40%(2/5), 95% CI:11.8-76.9%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>98.5%(66/67), 95% CI:92-99.7%</td></tr><tr><td rowspan=3 colspan=2>Recovering</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100%(1/1), 95% CI:20.7-100%</td></tr><tr><td rowspan=3 colspan=2>Previous Infection</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>298</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>296</td><td rowspan=1 colspan=1>99.3%(296/298), 95% CI:97.6-99.8%</td></tr><tr><td rowspan=3 colspan=2>No Infection</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>227</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>224</td><td rowspan=1 colspan=1>98.7%(224/227), 95% CI:96.2-99.5%</td></tr><tr><td rowspan=3 colspan=2>Indeterminate</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>52.6%(10/19), 95% CI:31.7-72.7%</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>100%(46/46), 95% CI:92.3-100%</td></tr></table>

PresedAcute Retrospective Samples: Plexus EBV vs. Consensus Predicate or VCA IgM anae Samples were collected and tested by Mid-West investigator $( { \mathfrak { n } } ^ { = 1 5 0 } )$

The following tableoutlines the positive and negative perent agrements or retrospecive samples for VCA IgM analyte when the consensus predicate is used for VCA IgM analysis.

<table><tr><td rowspan=1 colspan=6>Table 7: EBV VCA IgM Results</td></tr><tr><td rowspan=1 colspan=2>Consensus Predicate</td><td rowspan=1 colspan=3>Plexus</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Ⅱ</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>143</td><td rowspan=1 colspan=1>140</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>97.2%(40/144), 95% CI:93.1-98.9%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>33.3%(2/6), 95% C1:9.7-70.0%</td></tr><tr><td rowspan=1 colspan=1>No consensus</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>NA</td></tr></table>

No  l u $\cdots$ a 2/3 majority could not be obtained.

resAcute Retrospecive Samples: Plexus EBV vs. Heterophile Rapid Test o Heterophile IgM analye Samples were collected and tested by Mid-West investigator $( n = 1 5 0 )$ .

Theollowing tableoutines the positive n negative perent agrments or retropective amples or Hetil IgM analyte when the Heterophile rapid test is used as predicate for Heterophile $\mathbf { I g } \mathbf { M }$ analysis and consensus predicate is used for VCA $\mathbf { I g } \mathbf { M }$ analysis.

<table><tr><td rowspan=1 colspan=6>Table 8: EBV Heterophile Results</td></tr><tr><td rowspan=1 colspan=2>Predicate Rapid Test</td><td rowspan=1 colspan=3>Plexus</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>112</td><td rowspan=1 colspan=1>98</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>87.5%(98/112), 95% CI:80.1-92.4%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>92.1%(35/38), 95% CI:79.2-97.3%</td></tr></table>

Presed Acute Retrospective Samples: Plexus EBV vs. Consensus Predicate or VCA IgM analyt by Serolgical Status)   
Samples were collected and tested by Mid-West investigator $( n = 1 5 0 )$ .

The owing tabluihe posivnnegativ pernt greents cro vrus rologicass for retrospective samples for VCA IgM analyte when the consensus predicate is used for VCA $\mathbf { I g } \mathbf { M }$ analysis,

<table><tr><td rowspan=1 colspan=8>Table 9: EBV VCA IgM Results</td></tr><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Consensus Predicate</td><td rowspan=1 colspan=3>Plexus</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=2>Serological Status byPredicates</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=6 colspan=1>Acute</td><td rowspan=3 colspan=1>PrimaryAcute</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>104</td><td rowspan=1 colspan=1>103</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>99%(103/104), 95% CI:94.8-99.8%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>50%(1/2), 95% C1:9.5-90.5%</td></tr><tr><td rowspan=1 colspan=1>No conscnsus&#x27;</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=3 colspan=1>LateAcute</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>87.5%(7/8), 95% CI:52.9-97.8%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>No consensus</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=2>No Infection</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=2>No Infection</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>50%(1/2), 95% CI:9.5-90.5%</td></tr><tr><td rowspan=1 colspan=2>No Infection</td><td rowspan=1 colspan=1>No consensus</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=2>Indeterminate</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>93.8%(30/32), 95% CI:79.9-98.3%</td></tr></table>

# K073381

510(k) Summary of Safety and Effectiveness Plexus EBV IgM Multi-Analyte Diagnostics Catalog No. MP0600M Prepared Date: July 22, 2008 Page 11 of 13

<table><tr><td rowspan=1 colspan=7>Table 9: EBV VCA IgM Results</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Consensus Predicate</td><td rowspan=1 colspan=3>Plexus</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Serological Status byPredicates</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Indeterminate</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%(0/2), 95% CI:0-65.8%</td></tr><tr><td rowspan=1 colspan=1>Indeterminate</td><td rowspan=1 colspan=1>No consensus</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>NA</td></tr></table>

$2 / 3$ majority could not be obtained.

Presed Acute Retrospective Samples: Plexus EBV vs. Heterophile Rapid Test for Heterophile IgM analyte by Serological Status)

Samples were collected and tested by Mid-West investigator $( n { = } I 5 0 )$ .

The owigabulee poiivnegatve perntt rosvaoglcas for retrospective samples for Heterophile IgM analyte when the Heterophile rapid test is used as predicatc for Heterophile IgM analysis and consensus predicate is used for VCA $\mathbf { I g } \mathbf { M }$ analysis.

<table><tr><td rowspan=1 colspan=8>Table 10: EBV Heterophile IgM Results</td></tr><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Predicate HeterophileRapid Test</td><td rowspan=1 colspan=3>Plexus</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=2>Serological Status byPredicates</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=4 colspan=1>Acute</td><td rowspan=2 colspan=1>PrimaryAcute</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>86.2%(75/87), 95% CI:77.4-91.9%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>89.5%(17/19), 95% CI:68.6-97.1%</td></tr><tr><td rowspan=2 colspan=1>LateAcute</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>66.7%(2/3), 95% CI:20.8-93.9%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>100%(5/5), 95% CI:56.6-100%</td></tr><tr><td rowspan=1 colspan=2>No Infection</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=2>No Infection</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>U</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100%(2/2), 95% CI:34.2-100%</td></tr><tr><td rowspan=1 colspan=2>Indeterminate</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>95.5%(21/22), 95% C1:78.2-99.2%</td></tr><tr><td rowspan=1 colspan=2>Indeterminate</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>91.7%(1 1/12), 95% Cl:64.6-98.5%</td></tr></table>

# inter-laboratory, Intra-assay and Inter-assay Reproducibility

Theinter/intra-assay repducibility nd the inter-laboratoy reproducibility testng we performed a hre e the study are summarized in the table below.

<table><tr><td rowspan=1 colspan=12>Table 11: Inter-laboratory, Intra-assay and Inter-assay Reproducibility</td></tr><tr><td rowspan=1 colspan=6>Plexus VCA IgM</td><td rowspan=1 colspan=6>Plexus Heterophile Antibody</td></tr><tr><td rowspan=2 colspan=1>ID</td><td rowspan=1 colspan=3>Intra-assay &amp; Inter-assay%CV</td><td rowspan=1 colspan=2>Inter-Lab</td><td rowspan=2 colspan=1>ID</td><td rowspan=1 colspan=3>Intra-assay &amp; Inter-assay%CV</td><td rowspan=1 colspan=2>Inter-Lab</td></tr><tr><td rowspan=1 colspan=1>MeanIndex</td><td rowspan=1 colspan=1>Intra-assay</td><td rowspan=1 colspan=1>Inter-assay</td><td rowspan=1 colspan=1>MeanIndex</td><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>MeanIndex</td><td rowspan=1 colspan=1>Intra-assay</td><td rowspan=1 colspan=1>Inter-assay</td><td rowspan=1 colspan=1>MeanIndex</td><td rowspan=1 colspan=1>% CV</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>4.48</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>13.7%</td><td rowspan=1 colspan=1>4.48</td><td rowspan=1 colspan=1>8.8%</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>6.12</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>16.7%</td><td rowspan=1 colspan=1>6.12</td><td rowspan=1 colspan=1>14.1%</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>2.67</td><td rowspan=1 colspan=1>4.2%</td><td rowspan=1 colspan=1>15.0%</td><td rowspan=1 colspan=1>2.67</td><td rowspan=1 colspan=1>10.0%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>4.46</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>15.8%</td><td rowspan=1 colspan=1>4.46</td><td rowspan=1 colspan=1>10.2%</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2.08</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>18.7%</td><td rowspan=1 colspan=1>2.08</td><td rowspan=1 colspan=1>16.3%</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>2.19</td><td rowspan=1 colspan=1>5.0%</td><td rowspan=1 colspan=1>13.8%</td><td rowspan=1 colspan=1>2.19</td><td rowspan=1 colspan=1>1.9%</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>1.24</td><td rowspan=1 colspan=1>3.6%</td><td rowspan=1 colspan=1>13.2%</td><td rowspan=1 colspan=1>1.24</td><td rowspan=1 colspan=1>6.7%</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1.20</td><td rowspan=1 colspan=1>6.1%</td><td rowspan=1 colspan=1>15.8%</td><td rowspan=1 colspan=1>1.20</td><td rowspan=1 colspan=1>5.2%</td></tr><tr><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>1.12</td><td rowspan=1 colspan=1>4.4%</td><td rowspan=1 colspan=1>25.3%</td><td rowspan=1 colspan=1>1.12</td><td rowspan=1 colspan=1>9.0%</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>0.74</td><td rowspan=1 colspan=1>6.4%</td><td rowspan=1 colspan=1>14.0%</td><td rowspan=1 colspan=1>0.74</td><td rowspan=1 colspan=1>7.2%</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>5.2%</td><td rowspan=1 colspan=1>22.1%</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>16.0%</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0.55</td><td rowspan=1 colspan=1>5.7%</td><td rowspan=1 colspan=1>12.8%</td><td rowspan=1 colspan=1>0.55</td><td rowspan=1 colspan=1>3.3%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0.77</td><td rowspan=1 colspan=1>6.1%</td><td rowspan=1 colspan=1>28.2%</td><td rowspan=1 colspan=1>0.77</td><td rowspan=1 colspan=1>24.3%</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>8.3%</td><td rowspan=1 colspan=1>47.2%</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>47.8%</td></tr><tr><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>0.59</td><td rowspan=1 colspan=1>6.1%</td><td rowspan=1 colspan=1>46.8%</td><td rowspan=1 colspan=1>0.59</td><td rowspan=1 colspan=1>51.8%</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>5.6%</td><td rowspan=1 colspan=1>20.2%</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>3.8%</td></tr></table>

# K073381

# $5 1 0 ( \mathbf { k } )$ Summary of Safety and Effectiveness Plexus EBV IgM Multi-Analyte Diagnostics Catalog No. MP0600M Prepared Date: July 22, 2008 Page 12 of 13

<table><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>4.5%</td><td rowspan=1 colspan=1>68.4%</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>67.7%</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>8.5%</td><td rowspan=1 colspan=1>55.6%</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>9.0%</td></tr><tr><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>7.3%</td><td rowspan=1 colspan=1>122.4%</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>52.5%</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>10.5%</td><td rowspan=1 colspan=1>47.4%</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>23.6%</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>8.7%</td><td rowspan=1 colspan=1>45.6%</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>20.4%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>7.0%</td><td rowspan=1 colspan=1>77.7%</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>47.8%</td></tr></table>

# Inter-Lot Reproducibility

T p V kit. The results of the study are summarized in the table below.

<table><tr><td rowspan=1 colspan=6>Table 12: Inter-lot Reproducibility</td></tr><tr><td rowspan=1 colspan=3>Plexus VCA IgM</td><td rowspan=1 colspan=3>Plexus Heterophile Antibody</td></tr><tr><td rowspan=1 colspan=1>ID</td><td rowspan=1 colspan=1>Mean Index</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>ID</td><td rowspan=1 colspan=1>Mean Index</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>4.64</td><td rowspan=1 colspan=1>5.2%</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>5.65</td><td rowspan=1 colspan=1>3.8%</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>2.83</td><td rowspan=1 colspan=1>7.6%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>4.42</td><td rowspan=1 colspan=1>4.5%</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2.09</td><td rowspan=1 colspan=1>6.0%</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>2.05</td><td rowspan=1 colspan=1>4.3%</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>1.13</td><td rowspan=1 colspan=1>5.0%</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1.12</td><td rowspan=1 colspan=1>5.6%</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0.87</td><td rowspan=1 colspan=1>16.9%</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>0.78</td><td rowspan=1 colspan=1>7.2%</td></tr><tr><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0.84</td><td rowspan=1 colspan=1>17.5%</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0.54</td><td rowspan=1 colspan=1>10.6%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0.71</td><td rowspan=1 colspan=1>17.1%</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0.44</td><td rowspan=1 colspan=1>37.9%</td></tr><tr><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>24.4%</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>8.4%</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>19.4%</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>14.8%</td></tr><tr><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>16.0%</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>20.4%</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>19.3%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>18.8%</td></tr></table>

# Cross-Reactivity

A cros-reactivity study was perormed to determine fsamplesfrom varius disease states and oher potentially coss-eciviy cr tee wih st resuls when teste with hePeusV IM i pane fnt Antibody test (ANA) $\scriptstyle 1 = 2 8$ , Cytomegalovirus (CMV) $\mathtt { n } { = } 2 5$ , Herpes Simplex Virus-I (HSV-1) and Herpes Simplex Virus-2 (HSV-2) $\mathfrak { n } = 2$ , Rheumatoid Factor (Rh) ${ \mathfrak { n } } { = } 2 9$ , Rubella Virus $\mathtt { n } { = } 5$ , and Varicella-Zoster Virus (VZV) $\scriptstyle \mathfrak { n } = 4 2$ . sap  cnt ala s o civi   eusV the two (VCA and Heterophile) $\mathbf { I g M }$ analyte. The test samples were also evaluated on commercially available ELISA and hetrophile rapid tet.The ajorityo all smples that elicit a negative result were also confrme negative by the corresponding commerciay available tests, showing that the Plexus EBV IgM kit did not have additional cross-reactivity

<table><tr><td rowspan=1 colspan=9>Table 13: Cross-Reactivity</td></tr><tr><td rowspan=2 colspan=1>Cross Reactives</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Method</td><td rowspan=1 colspan=3>EBV VCA IgM</td><td rowspan=1 colspan=3>EBV Heterophile</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=3 colspan=1>ANA</td><td rowspan=3 colspan=1>28</td><td rowspan=1 colspan=1>Plexus</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>28</td></tr><tr><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>28</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=3>$2}$</td><td rowspan=1 colspan=3>0</td></tr><tr><td rowspan=3 colspan=1>Cytomegalovirus(CMV)</td><td rowspan=3 colspan=1>25</td><td rowspan=1 colspan=1>Plexus4</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>25</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=2>5}$</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>14</td></tr><tr><td rowspan=3 colspan=1>HSV 1 &amp; HSV 2</td><td rowspan=3 colspan=1>2</td><td rowspan=1 colspan=1>Plexus</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>0</td></tr><tr><td rowspan=2 colspan=1>Rheumatoid Factor(Rh)</td><td rowspan=2 colspan=1>29</td><td rowspan=1 colspan=1>Plexus</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>29</td></tr><tr><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>29</td></tr></table>

# K073381

# 510(k) Summary of Safety and Effectiveness Plexus EBV $\bf { I g M }$ Multi-Analyte Diagnostics Catalog No. MP0600M Prepared Date: July 22, 2008 Page 13 of 13

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=3>4</td><td rowspan=1 colspan=3>0</td></tr><tr><td rowspan=3 colspan=1>Rubella</td><td rowspan=3 colspan=1>5</td><td rowspan=1 colspan=1>Plexus</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td></tr><tr><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=3>0</td><td rowspan=1 colspan=3>0</td></tr><tr><td rowspan=3 colspan=1>Varicella-zoster(VZV)</td><td rowspan=3 colspan=1>42</td><td rowspan=1 colspan=1>Plexus</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>40</td></tr><tr><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>40</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=3>33$</td><td rowspan=1 colspan=3>0</td></tr></table>

Euioal Sampe; Euiocal Sples; eEquival Samples; O Ival S

# Sample Storage and Handling

Fifteen (15) negative and positive or EBV IgM samples were used to assess the reactivity of unfrozen sample agains smples hat weefozn and thawed for u tiveccs.No ect was bserved or y tethaw cycling in either the positive or negative sample.

# Interference

T    al s  poiv negative for EBV VCA IgM and heterophile antibody by Plexus EBV $\mathbf { I g } \mathbf { M }$ were used in the study. Baseline EBV IgM levels were established for each sample before interferents were added. Two concentration levels of each interferent were used: triglycerides ( $\mathrm { 1 ~ m g / m L }$ and $\mathbf { \Omega } ^ { \mathrm { 1 0 ~ m g / m L } }$ , albumin $\mathbf { \tilde { \Delta } } 6 \ \mathbf { m g } / \mathbf { m L }$ and $6 0 ~ \mathrm { m g / m L } )$ , bilirubin (0.02 $\mathrm { m g / m L }$ and $0 . 2 \mathrm { \ m g / m L } )$ , and hemoglobin $2 2 \mathrm { \ m g / m L }$ and $2 2 0 \mathrm { \ m g / m L } )$ The higher interferent concentrations p o i sample.

Focus Diagnostics, Inc. C/O Deborah Morris 10703 Progress Way Cypress, California 90630

Re: k073381 Trade/Device Name: Plexus EBV IgM Multi-Analyte Diagnostics Regulation Number: 21 CFR 866.3235 Regulation Name: Epstein-Barr Virus Serological Reagents Regulatory Class: Class I Product Code: LJN Dated: November 30, 2007 Received: December 3, 2007

Dear Ms. Morris:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket

Page 2 - Focus Diagnostics, Inc.

notification. The FDA finding of substantial equivalence of your device to a lcgally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRI's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-frec numbcr (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/ee617a99511f05a16626528f0add0b9b5b2c1c149f656ce0c42582f23e83c769.jpg)

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

Enclosure

510(k) Number (if known):

# K073381

Device Name:

# Plexus EBV IgM Multi-Analyte Diagnostics

Indications for Use: Focus Diagnostics' PlexusTM EBV IgM Multi-Analyte Diagnostics test kit is intended for qualitatively detecting the presence or absence of human IgM class antibodies to viral capsid antigen (VCA), and hcterophile antibodies in human sera. The test is indicated as an aid in the diagnosis of EBV infection and EBV-associated infectious mononucleosis.

The pcrformance of this assay has not been established for use in the diagnosis of nasopharyngeal carcinoma and Burkitt's lymphoma, for testing of immunocompromised patients, for use by a point of care facility or for use with automatcd equipment. This assay has not been evaluated for donor screening.

# Page 1 of 1